source
- Takeda narcolepsy pill receives DEA clearance as Oura-Lilly deal raises conflict concerns and Pfizer exits Canadian Premarin marketTakeda announced that its experimental narcolepsy medication has been cleared by the U.S. Drug Enforcement Administration, marking the first regulatory nod for a therapy aimed at treating excessive…
- HHS to allocate up to $4.9 million for ibogaine research targeting PTSDThe U.S. Department of Health and Human Services announced it will provide up to $4.9 million to support research on ibogaine, a psychedelic compound. The funding is intended to explore ibogaine’s…